↓ Skip to main content

Therapy for metastatic melanoma: the past, present, and future

Overview of attention for article published in BMC Medicine, March 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
15 news outlets
twitter
3 tweeters
patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
158 Dimensions

Readers on

mendeley
182 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Therapy for metastatic melanoma: the past, present, and future
Published in
BMC Medicine, March 2012
DOI 10.1186/1741-7015-10-23
Pubmed ID
Authors

Laura Finn, Svetomir N Markovic, Richard W Joseph

Abstract

Metastatic melanoma is the most aggressive form of skin cancer with a median overall survival of less than one year. Advancements in our understanding of how melanoma evades the immune system as well as the recognition that melanoma is a molecularly heterogeneous disease have led to major improvements in the treatment of patients with metastatic melanoma. In 2011, the US Food and Drug Administration (FDA) approved two novel therapies for advanced melanoma: a BRAF inhibitor, vemurafenib, and an immune stimulatory agent, ipilimumab. The success of these agents has injected excitement and hope into patients and clinicians and, while these therapies have their limitations, they will likely provide excellent building blocks for the next generation of therapies. In this review we will discuss the advantages and limitations of the two new approved agents, current clinical trials designed to overcome these limitations, and future clinical trials that we feel hold the most promise.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 182 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ecuador 2 1%
United States 2 1%
Australia 1 <1%
Germany 1 <1%
Romania 1 <1%
Denmark 1 <1%
Unknown 174 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 32 18%
Student > Ph. D. Student 31 17%
Student > Bachelor 28 15%
Researcher 24 13%
Student > Doctoral Student 13 7%
Other 31 17%
Unknown 23 13%
Readers by discipline Count As %
Agricultural and Biological Sciences 64 35%
Medicine and Dentistry 40 22%
Biochemistry, Genetics and Molecular Biology 28 15%
Pharmacology, Toxicology and Pharmaceutical Science 8 4%
Chemistry 3 2%
Other 11 6%
Unknown 28 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 119. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2017.
All research outputs
#111,657
of 12,517,134 outputs
Outputs from BMC Medicine
#103
of 2,010 outputs
Outputs of similar age
#1,234
of 144,425 outputs
Outputs of similar age from BMC Medicine
#1
of 26 outputs
Altmetric has tracked 12,517,134 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,010 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.9. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 144,425 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.